[In vitro induced activity of polymorphonuclear leukocyte myeloperoxidase at different stages of opisthorchis invasion and at stages of a different rehabilitative period].
Polymorphonuclear leukocytes from 115 patients with opisthrochiasis at its different (acute and chronic) stages were studied before and 1-3 days, 1-3 months, and 1-2 years after antihelminthic therapy with bilthricide. The functional activity of the cells in question was evaluated following an hour load with different drugs: bilthricide, ascorbic acid, decaris, cyclophosphane, doxycycline in a final concentration of 2.5 x 10(-5) mole/l. Physiological solution and autologous plasma were test controls. The changes in the activity of extracellular (secreted), intracellular (reserve), and summary myeloperoxidase on incubation with each test agent were found to depend on the stage of the disease and the interval after antihelminthic therapy. In early Opisthorchis invasion, the maximum increase in the induced activity of secreted myeloperoxidase is followed by a fall in the level of reserve myeloperoxidase in response to these drugs. With this, there is the most pronounced decrease in reserve myeloperoxidase of polymorphonuclear leukocytes in chronic opisthorchiasis, which may be due to the disrupted controlling processes of its production at late stages of the disease. The distinctive features of the action of agents on the overall activity of granular leukocytic myeloperoxidase in acute and chronic opisthorchiasis suggests that autologous plasma, ascorbic acid, and doxycycline should be used as a test control at the clinical stage of Opisthorchis invasion.
Iakovleva
V V
VV
Stepanova
T F
TF
Androsova
E V
EV
Shonin
A L
AL
Postnikova
T F
TF
D000871:Anthelmintics / Q000494:pharmacology / Q000627:therapeutic use; D000969:Antinematodal Agents / Q000494:pharmacology; D000975:Antioxidants / Q000494:pharmacology; D001205:Ascorbic Acid / Q000494:pharmacology; D015415:Biomarkers / Q000032:analysis; D002478:Cells, Cultured; D003520:Cyclophosphamide / Q000494:pharmacology; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007978:Levamisole / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D009889:Opisthorchiasis / Q000097:blood* / Q000188:drug therapy / Q000378:metabolism; D009195:Peroxidase / Q000032:analysis / Q000378:metabolism*; D011223:Praziquantel / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors
D000871:Anthelmintics; D000969:Antinematodal Agents; D000975:Antioxidants; D015415:Biomarkers; D007166:Immunosuppressive Agents; D007978:Levamisole; D011223:Praziquantel; D003520:Cyclophosphamide; D009195:Peroxidase; D001205:Ascorbic Acid